Sanofi takes its own drug pric­ing pledge, point­ing to a de­cline in their ag­gre­gate net price

Sanofi CEO Sanofi Olivi­er Brandi­court (left), flanked by CFO Jerome Con­t­a­mine, speaks dur­ing the pre­sen­ta­tion of the group’s 2016 re­sults in Paris on Feb­ru­ary 8, 2017. ER­IC PIER­MONT/AFP/Get­ty

What do you do when your in­dus­try is rou­tine­ly pil­lo­ried by the pres­i­dent of the US for be­ing run by a group of white col­lar price gougers, rou­tine­ly rip­ping off the Amer­i­can con­sumer?

In Big Phar­ma’s case, you be­gin to un­der­stand that those opaque drug prices you work with are a big part of the prob­lem, and you start to shed a light on the pric­ing menu, while com­mit­ting to an eth­i­cal ap­proach on pric­ing that might help cool the white-hot rhetoric.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER